Cell and gene therapies now account for 77% of the UK’s ongoing clinical trials, according to a newly released report and database from the Cell and Gene Therapy Catapult (CGT Catapult).
The UK therapies medicinal products (ATMPs) clinical trials database shows that the nation’s 127 ongoing trials account for 12% of the total global cell and gene therapy clinical studies.
The NHS and UK ecosystem are providing the right platforms to allow innovative therapies to progress through to the clinic in ever increasing numbers.
Cell and gene therapies require novel approaches, systems and infrastructure to enable the delivery of these life changing, living medicines to patients.
The favourable UK environment is being recognised internationally with the majority of commercially sponsored trials being backed by international organisations.
Cell and gene therapies continue to progress towards large scale commercialisation to add to the therapies already approved for use.
The database shows that 77% of UK cell and gene therapy trials are now sponsored by commercial organisations compared to only 25% in 2013.
This number reflects the continuous investment that companies are making in cell and gene therapies, and the transformative effects that these therapies are proving to have on patients’ lives.
The main indication for cell and gene therapies clinical trials remains oncology (39%) followed by ophthalmology (13%) and haematology (12%).
“These extraordinary figures show the UK’s life sciences sector is leading the world in getting cutting-edge treatments to NHS patients as quickly as possible,” said Health Minister Baroness Blackwood.
“As our research capabilities continue to grow, our exceptional NHS as a whole will be able to reap the benefits of not only more innovative medicines for patients, but investment from companies seeking outstanding expertise.”